Published in Endocrinology on July 01, 2002
Vitamin D and cancer: a review of molecular mechanisms. Biochem J (2012) 1.51
Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br J Pharmacol (2009) 1.37
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (2010) 1.32
Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res (2009) 1.24
1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol (2006) 1.22
Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol (2008) 1.17
Vitamin D and cancer. Front Endocrinol (Lausanne) (2012) 1.15
Vitamin D status and early age-related macular degeneration in postmenopausal women. Arch Ophthalmol (2011) 1.13
Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment. Cardiovasc Diabetol (2014) 0.95
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle (2010) 0.94
Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nutr Res Rev (2012) 0.93
Reconsidering the connection between vitamin D levels and age-related macular degeneration. Eye (Lond) (2011) 0.92
Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃. Exp Cell Res (2010) 0.88
Solar UV exposure and mortality from skin tumors. Adv Exp Med Biol (2008) 0.86
Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol (2010) 0.84
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment. Cancers (Basel) (2013) 0.83
Mechanistic Effects of Calcitriol in Cancer Biology. Nutrients (2015) 0.82
Vitamin D as a promising anticancer agent. Indian J Pharmacol (2011) 0.80
Autophagy enhancement contributes to the synergistic effect of vitamin D in temozolomide-based glioblastoma chemotherapy. Exp Ther Med (2016) 0.79
Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. Am J Physiol Endocrinol Metab (2013) 0.79
Prediction of Cis-Regulatory Elements Controlling Genes Differentially Expressed by Retinal and Choroidal Vascular Endothelial Cells. J Ocul Biol Dis Infor (2008) 0.79
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol (2005) 0.78
Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Sci Rep (2016) 0.77
Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol Ther (2013) 0.77
Solar ultraviolet exposure and mortality from skin tumors. Adv Exp Med Biol (2014) 0.77
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer. Cancer Prev Res (Phila) (2015) 0.76
High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease. Mediators Inflamm (2017) 0.75
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer (2007) 6.18
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics (2012) 2.97
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med (2007) 2.54
High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev (2002) 2.46
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res (2005) 2.34
Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem (2005) 2.28
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005) 2.23
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis (2003) 2.20
The costs and underappreciated consequences of research misconduct: a case study. PLoS Med (2010) 2.06
Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene (2004) 2.02
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol (2005) 1.69
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol (2008) 1.68
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology (2013) 1.52
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer (2009) 1.46
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A (2006) 1.46
The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am (2010) 1.37
Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol (2004) 1.35
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (2010) 1.32
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther (2004) 1.29
Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res (2009) 1.24
Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Res (2012) 1.18
Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem (2007) 1.15
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate (2004) 1.15
Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget (2013) 1.15
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.14
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate (2004) 1.14
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther (2002) 1.14
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther (2002) 1.14
Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A (2014) 1.14
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One (2011) 1.13
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis (2003) 1.13
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer (2006) 1.13
Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology (2004) 1.12
Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res (2010) 1.10
Gene therapy of carcinoma using ultrasound-targeted microbubble destruction. Ultrasound Med Biol (2011) 1.09
Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate (2010) 1.09
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol (2008) 1.08
Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate (2006) 1.07
Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res (2006) 1.07
Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis (2003) 1.07
Central quadrant procurement of radical prostatectomy specimens. Prostate (2009) 1.07
Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis (2008) 1.07
The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res (2006) 1.05
Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw (2006) 1.04
CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology (2010) 1.04
Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res (2006) 1.03
Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology (2007) 0.98
Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology (2002) 0.98
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer (2010) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
Vitamin D in combination cancer treatment. J Cancer (2010) 0.96
1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther (2008) 0.96
Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer Res (2008) 0.95
Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev (2002) 0.95
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol (2006) 0.95
Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int (2009) 0.95
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle (2010) 0.94
The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat (2011) 0.94
C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate (2003) 0.93
Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am J Pathol (2010) 0.93